How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,866 results for

Aspartate Aminotransferase

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Diagnosis and Management of Glycogen Stored Diseases type VI and IX a practice resource of ACMG

-hydroxybutyrate (ß-OHB) levels increase only modestly in GSD I 22,55 as it is considered a hypoketotic hypoglycemic state. In contrast, hyperketonemia with fasting hypoglycemia is more common in GSDs III, VI, and IX. 22 Hepatic transaminase levels (aspartate aminotrans- ferase [AST] and alanine aminotransferase [ALT]) are significantly higher in GSD III, VI, and IX as compared with GSD I.InGSD IAST andALT are usuallymodestlyincreased to ~100U/L in the early stages of the disease with a tendency to normalize (...) of fasting hypoglycemia, significant splenomegaly; storage cells characteristic of the disease, other features like bone and pulmonary involvement ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, GSD glycogen storage disease, PT prothrombin time. ACMG PRACTICE RESOURCE KISHNANI et al 6 Volume 0 | Number 0 | Month | GENETICS in MEDICINEhypoglycemia is indicated to rule out endocrine causes, particularly when hepatomegaly is not a significant feature. A more detailed workup

2019 American College of Medical Genetics and Genomics

264. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. Full Text available with Trip Pro

) (22) . ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; Cr = creatinine; mo = months; NSAID = nonsteroidal antiinflammatory drug; ULN = upper limits of normal; VKA = vitamin K antagonist; y = years. Assessment of Patient Thromboembolic Risk Patients who have had a stroke or venous thromboembolic event or have an underlying malignancy or a significant cardiovascular disease history are particularly prone to thrombotic events ( Table 1 ) ( x 8 Kearon, C., Akl

2019 Society of Interventional Radiology

266. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation

Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation Alanine aminotransferase (ALT) and aspartate aminotransferase (...) , have been reported in patients treated with tocilizumab; some cases required liver transplantation advise patients to seek medical help immediately if they experience signs and symptoms of liver injury, such as tiredness, abdominal pain, and jaundice monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at initiation, every 4–8 weeks during the first 6 months of treatment, and every 12 weeks thereafter in patients with rheumatological indications exercise caution when

2019 MHRA Drug Safety Update

267. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

aminotransferase (19% versus 39%), conjunctivitis (19% versus 4.0%), nausea (19% versus 22%) and increased aspartate aminotransferase (19% versus 36%). The most frequently reported serious adverse events in the dacomitinib and gefitinib groups respectively were: disease progression (3.5% versus 4.9%), diarrhoea (2.2% versus 0%), pleural effusion (2.2% versus 0.9%), pneumonia (2.2% versus 0.9%) and dyspnoea (0.4% versus 1.8%). 2 Three deaths were considered to be related to study treatment toxicity. Two

2019 Scottish Medicines Consortium

268. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

of statins. A genome-wide association study in participants from the SEARCH RCT evaluated 85 subjects who had developed definite myopathy (defined as muscle symptoms with CK >10 times the ULN) or “incipient myopathy” (defined as CK >3 times ULN and >5 times baseline levels, plus alanine aminotransferase [ALT] >1.7 times baseline levels without an elevated ALT alone at any other visit, with or without muscle symptoms) on simvastatin 80 mg and compared them with 90 participants who were also allocated

2019 American Gastroenterological Association Institute

270. AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

, B In HCV-infected pregnant women with pruritus or jaundice, there should be a high index of suspicion for intrahepatic cholestasis of pregnancy with subsequent assessment of alanine aminotransferase ALT , aspartate aminotransferase AST , and serum bile acids. I, B HCV-infected women with cirrhosis should be counseled about the increased risk of adverse maternal and perinatal outcomes. Antenatal and perinatal care should be coordinated with a maternal–fetal medicine (ie, high-risk pregnancy

2019 American Association for the Study of Liver Diseases

272. Nivolumab (melanoma) - Addendum to Commission A16-35

) Musculoskeletal and connective tissue disorders 96 (45.3) 94 (43.7) Arthralgia 39 (18.4) 33 (15.3) Back pain 20 (9.4) 28 (13.0) Respiratory, thoracic and mediastinal disorders 99 (46.7) 88 (40.9) Cough 44 (20.8) 42 (19.5) Dyspnoea 44 (20.8) 32 (14.9) Infections and infestations 98 (46.2) 83 (38.6) Nervous system disorders 89 (42.0) 88 (40.9) Headache 44 (20.8) 40 (18.6) Dizziness 23 (10.8) 18 (8.4) Investigations 106 (50.0) 69 (32.1) Alanine aminotransferase increased 40 (18.9) 12 (5.6) Aspartate (...) (9.4) 20 (9.3) Colitis 18 (8.5) 19 (8.8) General disorders and administration site conditions 23 (10.8) 13 (6.0) Fatigue 12 (5.7) 3 (1.4) Skin and subcutaneous tissue disorders 16 (7.5) 6 (2.8) Respiratory, thoracic and mediastinal disorders 19 (9.0) 6 (2.8) Infections and infestations 21 (9.9) 17 (7.9) Nervous system disorders 12 (5.7) 11 (5.1) Investigations 62 (29.2) 26 (12.1) Alanine aminotransferase increased 19 (9.0) 6 (2.8) Aspartate aminotransferase increased 16 (7.5) 4 (1.9) Lipase

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

275. Statins for children with familial hypercholesterolemia. Full Text available with Trip Pro

reduced the mean low-density lipoprotein cholesterol concentration at all time points (moderate quality evidence). Serum aspartate and alanine aminotransferase, as well as creatinine kinase concentrations, did not differ between treated and placebo groups at any time point (low quality evidence). The risks of myopathy (low quality evidence) and clinical adverse events (moderate quality evidence) were very low and also similar in both groups. In one study simvastatin was shown to improve flow-mediated

2017 Cochrane

276. Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

lipid traits; in 1 notable example, they found that loss-of-function variants in APOB were associated with decreased low-density lipoprotein cholesterol levels and triglyceride levels but also increased alanine and aspartate aminotransferase levels, consistent with hepatocyte injury. Notably, patients receiving the APOB -targeting medication mipomersen experience lower low-density lipoprotein cholesterol levels and, in some cases, elevated hepatic transaminases or other liver conditions

2018 American Heart Association

277. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Academy of Neurology AEs: adverse effects ALT: alanine aminotransferase ARRs: annualized relapse rates AST: aspartate aminotransferase CIS: clinically isolated syndrome CMSC: Consortium of Multiple Sclerosis Centers” COI: conflict of interest CV: curriculum vitae DMTs: disease-modifying therapies EDSS: Expanded Disability Status Scale FDA: US Food and Drug Administration GDDI: Guideline Development, Dissemination, and Implementation Subcommittee IOM: Institute of Medicine mIUs: milli-international (...) and unaffected controls. These differences include alterations in the proportions of regulatory T cells and different patterns of cytokine expression. Many CNS autoimmune diseases, such as neuromyelitis optica or N-methyl-D-aspartate receptor encephalitis, are associated with pathologic antibodies directed against a specific target. e8 However, in MS, all attempts at identifying antigen-specific targets have been unsuccessful, including logical potential candidates such as myelin proteins (e.g., myelin basic

2018 American Academy of Neurology

278. AASLD Guidelines for Treatment of Chronic Hepatitis B

to be used with similar antiviral activity, less systemic exposure, and thus decreased renal and bone toxicity. A phase 3 trial of 873 hepatitis B e antigen (HBeAg)‐positive patients (26% with past nucleos(t)ide analogue [NA] therapy) randomized to TAF 25 mg daily or TDF 300 mg daily in a 2:1 ratio found similar 48‐week responses, with serum HBV DNA <29 IU/mL in 64% versus 67%, alanine aminotransferase (ALT) normalization in 72% versus 67%, HBeAg loss in 14% versus 12%, and hepatitis B surface antigen

2018 American Association for the Study of Liver Diseases

279. Investigation and management of a raised serum ferritin

as for symptoms and signs that may point to an underlying inflammatory or malignant disorder. Initial investigations should include a full blood count, repeat SF, Tsat, renal function tests and LFTs (with viral hepatitis serology if LFTs are abnormal) and inflammatory markers, such as C‐reactive protein, erythrocyte sedimentation rate or plasma viscosity. Marked fluctuations in SF values and elevated aspartate aminotransferase rather than alanine aminotransferase, with increased GGT, are more typical

2018 British Committee for Standards in Haematology

280. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

on a large scale. For patients prior to treatment with a biologic Pre-treatment investigations Baseline assessment for all should include (grade 1C SOA 98%): laboratory evaluation of full blood count (FBC), creatinine/calculated glomerular filtration rate (GFR), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), albumin, tuberculin skin test (TST) or interferon-gamma release assay (IGRA) or both as appropriate, hepatitis B and C serology, and a chest radiograph. Baseline assessment

2018 British Society for Rheumatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>